The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
25 reports and counting
Diagonal Therapeutics Raises $125M Series B | Antibody Therapeutics
Biotech startup Diagonal Therapeutics secures $125 million Series B for rare genetic disease treatments.
Bambusa Therapeutics raises $90M Series A at $400M valuation
Bambusa Therapeutics raises $90M in Series A at $400M valuation. Bispecific antibodies for immunology...
Star Therapeutics raises $125M Series B at $600M valuation
Star Therapeutics raises $125M in Series B at $600M valuation. Antibody therapies for cancer...
AbCellera raises $555M Series B at $5.7B valuation
AbCellera raises $555M in Series B at $5.7B valuation. Antibody discovery platform...
Abcuro raises $200M Series C at $1.5B valuation
Abcuro raises $200M in Series C at $1.5B valuation. Antibody therapeutics for autoimmune diseases...
Star Therapeutics raises $125M Series D
Star Therapeutics raises $125M in Series D. Developing antibody therapies for autoimmune and inflammatory diseases...
ProfoundBio Raises $112M Series B
Clinical-stage oncology company developing antibody-drug conjugates (ADCs) for targeted cancer therapy
Upstream Bio raises $153M Series B at $800M valuation
Upstream Bio raises $153M in Series B at $800M valuation. Developing antibody therapeutics for inflammatory diseases...
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Showing 9 reports β’ Page 1 β’ Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.